Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Misses Expectations By $0.02 EPS

Compass Therapeutics (NASDAQ:CMPX) issued its quarterly earnings data on Monday. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02), FiscalAI reports.

Here are the key takeaways from Compass Therapeutics’ conference call:

• Compass said it is funded through 2028 for its development programs and is focused on advancing its four clinical-stage drugs toward data milestones.
• In the COMPANION-002 trial, tovecimig more than tripled the response rate and improved progression-free survival (PFS hazard ratio 0.44), but the overall-survival endpoint was not met. More than half of control-arm patients crossed over; a crossover-adjusted analysis showed a 0.85 hazard ratio, but the FDA has recommended a study demonstrating a survival advantage, and the company said it has not discussed the feedback with the agency.
• Compass is seeking to re-engage with the FDA on tovecimig’s regulatory path, which could include accelerated approval with a confirmatory study, a full-approval discussion, or no approval based on current data. The company hopes to provide an update in the coming months.
• The company expects new pipeline updates: CTX-8371 expansion-cohort data by year-end, a possible CTX-10726 update before the January JPMorgan meeting, and a Phase II study of biomarker-selected CTX-471 in neuroendocrine tumors, with data expected later in 2027. These programs remain early-stage, and management said clinical data will be needed to establish differentiation.

Compass Therapeutics Price Performance

CMPX stock opened at $0.84 on Tuesday. The stock has a market cap of $150.72 million, a price-to-earnings ratio of -2.09 and a beta of 1.06. The company has a 50 day simple moving average of $1.26 and a 200 day simple moving average of $3.08. Compass Therapeutics has a 1 year low of $0.67 and a 1 year high of $6.88.

Analysts Set New Price Targets

CMPX has been the topic of several recent analyst reports. Citigroup reiterated a “market outperform” rating on shares of Compass Therapeutics in a report on Wednesday, September 23rd. Wall Street Zen downgraded shares of Compass Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Lifesci Capital lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 22nd. Guggenheim reduced their price target on shares of Compass Therapeutics to $4.00 and set a “buy” rating for the company in a report on Wednesday, September 23rd. Finally, Citizens Jmp lowered their price objective on shares of Compass Therapeutics to $4.00 and set a “market outperform” rating for the company in a research report on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.25.

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.